Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
Speaker 2: The Stock Movers Report, your roundup of companies making moves
Speaker 2: in the stock market. Harnessing the power of Bloomberg Data.
Speaker 3: Let's take a look at what's happening in the marketplace
Speaker 3: today on Paul Swiney alongside Alexis Christoffers. We're joined by
Speaker 3: Bloomberg's Billy Lipscholtz. Billy, what are you looking at today?
Speaker 1: I want to start with Intel, the story of the
Speaker 1: day right now, up about twenty five percent, biggest intra
Speaker 1: day jump since nineteen eighty seven. This coming after Nvidia
Speaker 1: unveiling plans to invest five billion dollars in plans to
Speaker 1: co design chips. A big move, Paul, for what has
Speaker 1: been really a company that struggled for the last few years,
Speaker 1: though you do have that big government stake plans to
Speaker 1: take about it a ten percent stake in the company.
Speaker 1: Add onto this, a big rebound for the stock, but
Speaker 1: still kind of looks a bit like an EKG to
Speaker 1: me when you look at where this thing has been
Speaker 1: trading over the last two years.
Speaker 3: Got Novo Nordisk on the move today, I guess it's
Speaker 3: it's we keep going back and forth with these companies
Speaker 3: in their typees drugs or weight loss drugs.
Speaker 1: What's the news there. It's a bit of a two
Speaker 1: horse race. Novo Nordisk ADRs ticker Envo rallying more than
Speaker 1: six percent today. This coming after a study showed that
Speaker 1: its diabetes drug outperformed Eli Lilly's so ozempic. That's the
Speaker 1: Novo drug outperforming Eli Lilly's older drug, Trulyicity, and a
Speaker 1: real world survey of certain US patients this showed that
Speaker 1: Medicare patients who took ozempic were twenty three percent less
Speaker 1: likely to have a heart attack or stroke. So seeing
Speaker 1: some positive news there. One thing to keep an eye on, though,
Speaker 1: Novo Nordisk. Again, while it is up more than six
Speaker 1: percent today biggest jump since August, still down fifty three
Speaker 1: percent in the last twelve months. So these are two
Speaker 1: stocks that really rote a lot of momentum and that
Speaker 1: has fallen pretty flat.
Speaker 3: But I think the next thing in this whole weight
Speaker 3: loss thing is the pill that's going to make it,
Speaker 3: I would think easier for a lot of people to take,
Speaker 3: so that broadens the market, hopefully a lower cost maybe
Speaker 3: eventually to consumers. That could be like the second derivatively
Speaker 3: or second wave of this whole thing.
Speaker 1: Well, and that's been the big issue with these two
Speaker 1: companies is that you saw over the last few years
Speaker 1: so much excitement around ozembic. But as a person who
Speaker 1: covered biotech and healthcare for the first five years of
Speaker 1: my career here at Bloomberg, there's always a question of
Speaker 1: what the next generation is. Who's going to be the
Speaker 1: company that kind of drives that into the pioneer. So
Speaker 1: the big question is, to your point, who and when
Speaker 1: will bring an oral medicine to market?
Speaker 3: Yeah, that's gonna because I mean, you walk around now
Speaker 3: and you see someone who maybe could benefit from this,
Speaker 3: and you wonder why they are not taking And there's
Speaker 3: could be a million reasons, but one of them I
Speaker 3: would think would be just kind of the they don't
Speaker 3: like shocks, maybe the cost is too high and things
Speaker 3: like that. So you said that they continue to move
Speaker 3: that forward. That could be big for a lot more
Speaker 3: people speaking of I don't know, let's go tack about it.
Speaker 3: Because I'm a huge fan.
Speaker 1: As everyone you're a fan, I'm a huge fan. I
Speaker 1: go back and forth. I don't know about you between
Speaker 1: the chicken frieds taking the chicken and dumblings.
Speaker 3: I'm a country country boy breakfast, that's kind of what's
Speaker 3: my go to. I love it, but can I admit
Speaker 3: I've never eaten at Cracker Barrel.
Speaker 1: There's not one in Manhattan.
Speaker 3: That's the challenge.
Speaker 1: Well, why do you leave Manhattan?
Speaker 3: You do love, you do get off the rock.
Speaker 1: But to your boy, Cracker Barrel tickers CVRL under a
Speaker 1: bit of pressure, down just about two percent right now,
Speaker 1: though it is trading at the lowest level since early May.
Speaker 1: Is coming after the company laid out a weaker than
Speaker 1: expected forecast, showing lingering issues related to that logo backlash.
Speaker 1: The company projecting revenue for fiscal twenty twenty six between
Speaker 1: three point three to five billion and three point four
Speaker 1: to five billion. Analysts we're above that with just about
Speaker 1: three and a half billion dollars, so falling short again.
Speaker 1: Big question is how do they kind of deal with
Speaker 1: the fallout from that rebranding, given that we did see
Speaker 1: some data from the same store sales and foot traffic
Speaker 1: showing that there actually was a pretty notable drop.
Speaker 2: The stockmover's report from Bloomberg Radio. Check back with us
Speaker 2: throughout the day for the latest roundup of companies making
Speaker 2: news on Wall Street and for the latest market moving headlines.
Speaker 2: Listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg
Speaker 2: dot com, and on Applecarplay and Android Auto with the
Speaker 2: Bloomberg Business app.